Naibec's First Half Sales Increase 125% Compared to Same Period Last Year

[Asia Economy Reporter Hyungsoo Park] Peptide fusion bio company Nivec achieved strong performance in the first half of this year.

Nivec announced on the 12th that its cumulative sales in the first half of this year reached 12.9 billion KRW, an increase of 125.2% compared to the same period last year. Operating profit was 2.3 billion KRW, and net profit was 2.3 billion KRW.

In the second quarter, sales recorded 5.5 billion KRW, a 57.3% increase compared to the same period last year. During the same period, operating profit was 700 million KRW, and net profit was 1 billion KRW.

An official stated, "Exports of European-oriented bone regeneration bio materials such as OCS-B collagen have increased," adding, "Nivec supplies high value-added bio material products to the global market, including Europe, in partnership with the world's top implant companies ‘Straumann’ and ‘Nobel Biocare’."

Recently, the OCS-B collagen product secured excellent clinical data in the ‘Post-Marketing Clinical Follow-up (PMCF)’ trials ongoing in Europe and Korea, proving its safety and therapeutic efficacy.

In June, Nivec confirmed through clinical trials of OCS-B collagen conducted in Germany and Korea that out of a total of 108 patients, clinical data from 98 patients (90.7%) showed sufficient bone formation without side effects.

A Nivec official said, "Based on excellent product competitiveness, Nivec achieved favorable results in the second quarter following the first quarter," and added, "From the second half of the year, sales activities and exports in the Chinese and other Greater China markets are expected to resume."